New Products

Acorda celebrates an FDA OK — so does that make them a takeover target?

Late Friday, with the government shutdown looming, the biotech reported that the FDA has approved their inhaled levodopa therapy Inbrija for Parkinson’s patients, putting the company on a short path to a crucially needed market launch.

Ron Cohen, Acorda CEO

Acorda $ACOR had been looking at a PDUFA date in early January. But with the FDA racking up a record number of approvals this year — and its third on Friday — the company was given a little bit of an added edge for its 2019 rollout.

They need it.

The FDA held up their decision on Inbrija twice, first with a refuse-to-file on the application and later with an extension on the original PDUFA date. Meanwhile, Acorda lost patent protection on its only marketed product, Ampyra, making Inbrija a bridge to its ability to stay in business.

Paul Matteis

The big question for some of the analysts covering the company — after a big sigh of relief on the approval — is whether Acorda with its newly approved therapy gets marked out for a takeover.

Paul Matteis at Stifel put the 2022 sales consensus at $300 million, marking this as a possible takeout drug in a busy market — though well short of blockbuster status. 

Acorda’s shares jumped 5% in pre-market trading Monday.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->